Bayer sets sights on ¥200bn pharma target in Japan
This article was originally published in Scrip
Executive Summary
Bayer Yakuhin, Bayer's pharmaceutical subsidiary in Japan, is confident that its sales will surpass the ¥200 billion ($2.14 billion) mark in Japan this year, driven mainly by expected sales growth for new products Xarelto (rivaroxaban), Eylea (aflibercept) and Stivarga (regorafenib).